Article
Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.
Inflammopharmacology - 1 Feb 2022
Khodabakhsh Pariya, Khoie Nilgoon, Dehpour Ahmad-Reza, Abdollahi Alireza, Ghazi-Khansari Mahmoud, Shafaroodi Hamed
Abstract excerpt
Irritable bowel syndrome (IBS) is a functional gut disorder with multi-factorial pathophysiology that causes recurring pain or discomfort in the abdomen, as well as altered bowel habits. Montelukast, a well-known cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is widely used for the anti-inflammatory management of asthma. The present study aimed to evaluate the effects of pharmacological inhibition of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
